호르몬 피임약 시장 : 시장 분석 및 예측 - 유형별, 제품별, 기술별, 용도별, 최종 사용자별, 형태별, 재료 유형별, 의료 기기별(-2035년)

Hormonal Contraceptives Market is anticipated to expand from $24.5 billion in 2024 to $36.7 billion by 2034, growing at a CAGR of approximately 4.3%. The Hormonal Contraceptives Market encompasses pharmaceutical products designed to prevent pregnancy by regulating hormonal activity. This market includes oral pills, injectables, patches, and implants that deliver hormones to inhibit ovulation. Increasing awareness, evolving societal norms, and advancements in drug delivery systems are propelling growth. The market is also driven by rising demand for personalized medicine and long-acting reversible contraceptives, reflecting a shift towards more convenient and reliable family planning solutions.

The Hormonal Contraceptives Market is experiencing robust growth, propelled by evolving consumer preferences and advancements in pharmaceutical technologies. The oral contraceptive pills segment leads the market, driven by their ease of use and widespread availability. Within this segment, combination pills are particularly dominant due to their effectiveness and minimal side effects. Injectable contraceptives are the second-highest performing sub-segment, gaining popularity for their long-acting nature and convenience. The increasing awareness of reproductive health and family planning is fostering demand for diverse contraceptive options. The market is also witnessing innovation with the emergence of new delivery systems, such as transdermal patches and vaginal rings, which offer alternative methods for hormone delivery. Moreover, the growing emphasis on personalized medicine is encouraging the development of tailored contraceptive solutions. This trend is expected to enhance user satisfaction and adherence, further driving market growth and presenting lucrative opportunities for stakeholders.

The hormonal contraceptives market is characterized by a diverse array of products, with oral pills maintaining a significant share. Pricing strategies vary, influenced by brand positioning and regional economic conditions. New product launches focus on improved efficacy and reduced side effects, reflecting advancements in pharmaceutical research. The market is witnessing a shift towards long-acting reversible contraceptives, driven by user preference for convenience and reliability. Competition is intense, with major firms like Bayer, Pfizer, and Merck leading the charge. These companies are investing heavily in R&D to maintain their competitive edge. Regulatory frameworks, particularly in North America and Europe, play a critical role in shaping market dynamics. Stringent approval processes impact the speed of new product introductions. Emerging markets present growth opportunities, driven by increasing awareness and accessibility. The interplay of these factors underscores the complexity and potential of the hormonal contraceptives market.

Geographical Overview:

The hormonal contraceptives market is experiencing diverse growth across various regions, each presenting unique opportunities. North America dominates the market, driven by high awareness and accessibility of contraceptive methods. The region's robust healthcare infrastructure and favorable government policies further bolster market growth. Europe follows, with increasing demand for hormonal contraceptives due to rising awareness and supportive healthcare policies. The region's focus on women's health and reproductive rights strengthens its market position. In Asia Pacific, the market is expanding rapidly, fueled by a growing population and increased awareness of family planning. Governments are actively promoting contraceptive use to manage population growth. Latin America and the Middle East & Africa are emerging markets with substantial potential. In Latin America, improving healthcare access and rising awareness are driving market growth. Meanwhile, the Middle East & Africa are recognizing the importance of family planning, with governments implementing initiatives to enhance contraceptive accessibility and education.

The global hormonal contraceptives market is navigating complex geopolitical landscapes, with tariffs and trade tensions influencing strategic shifts in Asia. In Japan and South Korea, reliance on imported hormonal ingredients is prompting investments in local production capabilities to mitigate tariff impacts. China, under pressure from Western trade policies, is enhancing its domestic pharmaceutical manufacturing, aiming for self-reliance. Taiwan's strategic position in pharmaceutical supply chains is challenged by regional tensions, necessitating robust contingency planning. The parent market is experiencing steady growth, driven by increasing global demand for women's health products. By 2035, the market is expected to evolve with a focus on innovation and regional partnerships. Meanwhile, Middle East conflicts continue to affect global supply chains, indirectly influencing energy prices and manufacturing costs.

Key Trends and Drivers:

The hormonal contraceptives market is experiencing notable growth, driven by increasing awareness and acceptance of family planning. Key trends include the rising demand for long-acting reversible contraceptives (LARCs) and the development of novel hormonal formulations. These innovations aim to enhance efficacy and reduce side effects, appealing to a broader demographic. Furthermore, digital health platforms are gaining traction, providing remote consultations and prescription services, thus improving accessibility and convenience for consumers. Drivers of this market include the global emphasis on women's health and empowerment, with governments and NGOs advocating for reproductive rights. The growing urban population and changing lifestyles contribute to the increased adoption of hormonal contraceptives. Additionally, technological advancements in drug delivery systems are enhancing user experience and compliance. Opportunities abound in emerging markets where unmet needs for effective contraceptive solutions are significant. Companies investing in education and awareness campaigns are likely to capture a larger market share. Moreover, collaborations between pharmaceutical companies and healthcare providers are fostering innovation and expanding market reach. As societal norms evolve, the demand for personalized and discreet contraceptive options is expected to rise, further propelling market growth. The hormonal contraceptives market is poised for sustained expansion, supported by continuous research and development efforts.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Form
• 2.7 Key Market Highlights by Material Type
• 2.8 Key Market Highlights by Device

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Combined Oral Contraceptives
  • 4.1.2 Progestin-Only Pills
  • 4.1.3 Emergency Contraceptives
  • 4.1.4 Injectable Contraceptives
  • 4.1.5 Transdermal Patches
  • 4.1.6 Vaginal Rings
  • 4.1.7 Implants
  • 4.1.8 Intrauterine Devices (IUDs)
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Pills
  • 4.2.2 Injections
  • 4.2.3 Patches
  • 4.2.4 Rings
  • 4.2.5 Implants
  • 4.2.6 IUDs
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Hormonal Release Systems
  • 4.3.2 Biodegradable Implants
  • 4.3.3 Microchip Technology
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Birth Control
  • 4.4.2 Menstrual Regulation
  • 4.4.3 Endometriosis Management
  • 4.4.4 Acne Treatment
  • 4.4.5 Hormone Replacement Therapy
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Clinics
  • 4.5.3 Homecare
  • 4.5.4 Pharmacies
• 4.6 Market Size & Forecast by Form (2020-2035)
  • 4.6.1 Solid
  • 4.6.2 Liquid
  • 4.6.3 Patch
  • 4.6.4 Ring
  • 4.6.5 Implant
  • 4.6.6 Device
• 4.7 Market Size & Forecast by Material Type (2020-2035)
  • 4.7.1 Synthetic Hormones
  • 4.7.2 Natural Hormones
  • 4.7.3 Biodegradable Polymers
• 4.8 Market Size & Forecast by Device (2020-2035)
  • 4.8.1 Hormonal IUDs
  • 4.8.2 Non-Hormonal IUDs
  • 4.8.3 Injectable Devices

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Form
    • 5.2.1.7 Material Type
    • 5.2.1.8 Device
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Form
    • 5.2.2.7 Material Type
    • 5.2.2.8 Device
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Form
    • 5.2.3.7 Material Type
    • 5.2.3.8 Device
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Form
    • 5.3.1.7 Material Type
    • 5.3.1.8 Device
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Form
    • 5.3.2.7 Material Type
    • 5.3.2.8 Device
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Form
    • 5.3.3.7 Material Type
    • 5.3.3.8 Device
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Form
    • 5.4.1.7 Material Type
    • 5.4.1.8 Device
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Form
    • 5.4.2.7 Material Type
    • 5.4.2.8 Device
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Form
    • 5.4.3.7 Material Type
    • 5.4.3.8 Device
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Form
    • 5.4.4.7 Material Type
    • 5.4.4.8 Device
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Form
    • 5.4.5.7 Material Type
    • 5.4.5.8 Device
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Form
    • 5.4.6.7 Material Type
    • 5.4.6.8 Device
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Form
    • 5.4.7.7 Material Type
    • 5.4.7.8 Device
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Form
    • 5.5.1.7 Material Type
    • 5.5.1.8 Device
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Form
    • 5.5.2.7 Material Type
    • 5.5.2.8 Device
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Form
    • 5.5.3.7 Material Type
    • 5.5.3.8 Device
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Form
    • 5.5.4.7 Material Type
    • 5.5.4.8 Device
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Form
    • 5.5.5.7 Material Type
    • 5.5.5.8 Device
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Form
    • 5.5.6.7 Material Type
    • 5.5.6.8 Device
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Form
    • 5.6.1.7 Material Type
    • 5.6.1.8 Device
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Form
    • 5.6.2.7 Material Type
    • 5.6.2.8 Device
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Form
    • 5.6.3.7 Material Type
    • 5.6.3.8 Device
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Form
    • 5.6.4.7 Material Type
    • 5.6.4.8 Device
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Form
    • 5.6.5.7 Material Type
    • 5.6.5.8 Device

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Mithra Pharmaceuticals
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Afaxys
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Theramex
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Exeltis
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Gedeon Richter
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Mayne Pharma
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Lupin Pharmaceuticals
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 HLL Lifecare
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Cipla
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Sun Pharmaceutical Industries
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Famy Care
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Piramal Enterprises
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Zydus Cadila
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Torrent Pharmaceuticals
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Aurobindo Pharma
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Bayer Zydus Pharma
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Organon
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Durex
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 HRA Pharma
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Viatris
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us